249922-60-9

Basic information

• Product Name: 1-Butanol, 2-[bis(phenylmethyl)amino]-, (2S)-
• CAS NO: 249922-60-9
• Molecular Formula: C18H23NO
• Molecular Weight: 269.387
• Mol File: 249922-60-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Butanol, 2-[bis(phenylmethyl)amino]-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 2-[bis(phenylmethyl)amino]-, (2S)-(249922-60-9)
• EPA Substance Registry System: 1-Butanol, 2-[bis(phenylmethyl)amino]-, (2S)-(249922-60-9)

Safety Data

• Hazardous Substances Data: 249922-60-9(Hazardous Substances Data)

Upstream product

• 5856-62-2 (S)-2-aminobutan-1-ol 
• 100-39-0 benzyl bromide 
• 103-49-1 dibenzylamine 
• 205748-23-8 (R)-O-(2-bisphenylmethylamino)butyrylpantolactone 

Downstream Products

• 1070791-07-9 (2R,3S)-3-(dibenzylamino)pentan-2-ol 
• 257882-09-0 (3S,4S)-4-N,N-dibenzylamino-3-hexanol 
• 378752-92-2 (S)-2-(dibenzylamino)butanal 

Relevant articles and documents

Palladium-N-heterocyclic carbene (NHC)-catalyzed asymmetric synthesis of indolines through regiodivergent C(sp3)-H activation: Scope and DFT study

Two bulky, chiral, monodentate N-heterocyclic carbene ligands were applied to palladium-catalyzed asymmetric C-H arylation to incorporate C(sp3)-H bond activation. Racemic mixtures of the carbamate starting materials underwent regiodivergent reactions to afford different trans-2,3- substituted indolines. Although this CAr-Calkyl coupling requires high temperatures (140-160°C), chiral induction is high. This regiodivergent reaction, when carried out with enantiopure starting materials, can lead to single structurally different enantiopure products, depending on the catalyst chirality. The C-H activation at a tertiary center was realized only in the case of a cyclopropyl group. No C-H activation takes place alpha to a tertiary center. A detailed DFT study is included and analyses of methyl versus methylene versus methine C-H activation is used to rationalize experimentally observed regio- and enantioselectivities.

COMPOUNDS

The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and formula (a) where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

4,5-Dialkylsubstituted 2-imino-1,3-thiazolidine derivatives as potent inducible nitric oxide synthase inhibitors

In the course of our search for selective iNOS inhibitors, we have previously reported that 2-imino-1,3-oxazolidine derivatives (1) and 2-aminothiazole derivatives (2) are selective iNOS inhibitors. In order to find more potent iNOS inhibitors, we focused